# KIVU-107

Source: https://onco.cc/drugs/kivu-107/  
OnCo record `kivu-107` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

KIVU-107 is an experimental antibody-drug conjugate from Kivu Bioscience, in phase 1 trials for advanced solid tumours.

## Summary

KIVU-107 is an antibody-drug conjugate (site-specific, GlycoConnect and HydraSpace) from Kivu Bioscience. An antibody-drug conjugate against PTK7, built with site-specific GlycoConnect and HydraSpace conjugation for a precise, stable drug-to-antibody ratio. Its furthest stage is phase 1, for advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: KIVU-107
- Modality: Antibody-drug conjugate (site-specific, GlycoConnect and HydraSpace)
- Mechanism: An antibody-drug conjugate against PTK7, built with site-specific GlycoConnect and HydraSpace conjugation for a precise, stable drug-to-antibody ratio.

## Sources

- Kivu Bioscience: kivubioscience.com: https://kivubioscience.com/news/kivu-bioscience-to-present-preclinical-data-on-next-generation-adc-programs-at-aacr-annual-meeting-2026/
- Kivu Bioscience: gimv.com: https://www.gimv.com/en/node/4920
- ClinicalTrials.gov: trials of KIVU-107: https://clinicaltrials.gov/search?intr=KIVU-107

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [PTK7](https://onco.cc/targets/ptk7/)
- companies: [Kivu Bioscience](https://onco.cc/companies/kivu-bioscience/)
- trials: [A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct07229313/)

---
JSON: https://onco.cc/api/v1/entities/kivu-107.json